Metabolism Disorder TRIZ Cases

A serum-free culture method enriches vascular endothelial progenitor cells using specific growth factors.

Specific activators of MKK3, MKK4, or MKK6 increase p38 MAPK activity to enhance glucose tolerance.

Administering GM-CSF reduces pancreatic islet amyloid deposition in type 2 diabetes treatment.

A humanized anti-Siglec-15 antibody binds to target proteins on osteoclasts to block their formation and maturation.

Targeted integration into the albumin safe harbor locus prevents oncogene activation and gene silencing risks associated with random insertion.

Adsorbent materials remove lead and arsenic from beta-hydroxybutyrate salts to ensure safe dietary supplement purity.

Ladostigil reduces systemic inflammation and pro-inflammatory mediators without severe side effects of conventional agents.

Double-acylated GLP-1 derivatives attach protracting moieties to lysine residues via linkers, resolving oral bioavailability limits.

Magnesium compounds and EDTA dissociate insulin hexamers into monomers, accelerating absorption while minimizing injection site pain.

Lipid excipients form a non-lamellar liquid crystalline phase that extends setmelanotide release duration, resolving rapid release bottlenecks.

A lipid composition with tocopherol and alpha-linolenic acid lowers blood markers.

A composite herbal composition improves glucose uptake by muscle cells.

A pharmaceutical composition combining leucine, metformin, and sildenafil reduces hepatic steatosis by enhancing fat metabolism.

Liraglutide lowers cardiovascular death and heart failure risk by addressing unmet efficacy needs in diabetic vascular disease management.

Weekly basal insulin-Fc administration reduces hypoglycemia risk and improves glycemic control.

Calcium salt of D-glyceric acid activates GLYCTK1 enzymes to increase ATP production while reducing reactive oxygen species formation.

A bisamide derivative of dicarboxylic acid stimulates tissue regeneration and restores diminished organ function.

Enzymatic hydrolysis of phytate lowers ammonia emissions and phosphorus excretion while improving animal growth rates.

Bioadhesive polymer layers maintain residence time on the oral mucosa, ensuring continuous insulin release without digestive degradation.

Dual agonist peptide improves weight loss and glucose control by merging glucagon and GLP-1 receptor activities.

Targeted mutations block backbone cleavage, resolving molecular stability trade-offs in regenerative therapies.

PM20D1 enzyme activates brown fat thermogenesis independently of UCP1 to treat metabolic disorders.

A calcium composition uses a TRP agonist to increase calcium flux through the ruminal mucosa.

A Trim31 E3 ligase composition degrades RHBDF2 to resolve metabolic disorders.

A codon-optimized human insulin gene sequence enables continuous endogenous insulin production through recombinant adeno-associated viral vector delivery.

Linking GDF15 to an Fc region extends serum half-life, reducing injection frequency for metabolic disease treatment.

Botanical extracts modulate glucose homeostasis by isolating bioactive components to enhance insulin signaling while minimizing hypoglycemia risks.

Nogo-B inhibitor modulates ChREBP expression to prevent organ damage without hypoglycemia or weight gain side effects.

High-palmitic sucrose polyester compositions reduce solids at body temperature to eliminate waxy mouthfeel while maintaining calorie reduction in food products.

Acylation at defined positions maintains potency while extending half-life, resolving the trade-off between stability and receptor selectivity.

A food composition containing dietary fibers and specific vitamins supports post-partum weight management.

Antibody-drug conjugates deliver GLP1 peptidomimetics via non-cleavable linkers, extending action duration while minimizing off-target side effects.

Engineered FGF21 proteins promote insulin-independent glucose uptake to treat metabolic diseases.

Combining aprocitentan with an SGLT-2 inhibitor creates a pharmaceutical composition that mitigates fluid retention side effects.

Removing glycerol from insulin formulations prevents degradation while alternative excipients maintain solubility, extending shelf life.

A metabolite panel biomarker analysis method determines insulin resistance levels using polynomic algorithms to compare sample data against reference profiles.

Hedychium coronarium ethanol extract lowers blood glucose and boosts insulin without causing hypoglycemia in fasting subjects.

Conjugating a GLP-1 receptor agonist with an albumin-binding moiety extends half-life while retaining biological activity for metabolic treatment.

A pharmaceutical composition merges standardized Garcinia, Cyperus, and Coleus extracts to reduce body weight and increase lean mass.

A selective alpha-1 adrenoceptor antagonist relaxes prostate smooth muscle to improve urine flow in benign prostatic hyperplasia patients.

GI bitter taste receptor ligands modulate metabolic hormone release via receptor binding, addressing challenges in precise regulation of secretion.

A polypeptide antagonist inhibits the Na/K-ATPase and Src receptor complex to reduce adiposity.

Adult peripheral blood mononuclear cells acquire pluripotency markers in defined media without feeder layers, avoiding ethical concerns and immune rejection.

Specific amino acids and organic acids enhance mitochondrial function to treat metabolic disorders.

Replacing endogenous sequences with human GLP1R genes resolves species differences, ensuring accurate clinical trial outcome predictions.

Branched-chain amide modifications stabilize the polypeptide, extending half-life and resolving degradation issues in diabetes treatment.

A chiral iridium complex catalyzes asymmetric hydrogenation of trimethylpentadeca-trien-one isomers to produce high-purity tocopherol intermediates.

Continuous high gravity emulsification under nitrogen prevents thermal degradation and stratification, ensuring stable vitamin A microcapsules.

Combining DYRK1A and TGFβ inhibitors drives human beta cell proliferation rates up to 20 percent per day.